Management of transfusion-dependent myelodysplastic syndromes: Current and emerging strategies

American Journal of Cancer

Volumn 5, Issue 2, 2006, Pages 71-80

  Elkabani, Magda ^a   List, Alan F ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZACITIDINE; BEVACIZUMAB; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; INFLIXIMAB; LENALIDOMIDE; LONAFARNIB; METHYLTRANSFERASE INHIBITOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RETINOIC ACID; SCIO 469; SEMAXANIB; SODIUM PHENYLBUTYRATE; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB; TLK 199; UNCLASSIFIED DRUG; VALPROIC ACID; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; EPIGENETICS; GRANULOCYTOPENIA; HEMATOPOIESIS; HUMAN; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKEMOGENESIS; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VOMITING;

EID: 34547557306     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605020-00001     Document Type: Review

References (98)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias: French-American-British (FAB) Cooperative Group. Br J Haematol 1976; 33: 451-8
2. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004; 104: 579-85
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997 Mar 15; 89 (6): 2079-88
4. List AF, Vardiman J, Issa JP, et al. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2004; 297-317
5. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-4
6. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy measurement system: properties, applications, and interpretation. Health Qual Life Ouctomes 2003 Dec 16; 1 (1): 79
7. Kornblith AB, Herndon II JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441-52
8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment for Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85 (5): 365-76
9. Gattermann N, Porter J, Lopes L, et al. Iron overload in myelodysplastic syndromes. Hematology/Oncology Clinics 2005; 19 Suppl. 1: 5-27
10. Schafer AI, Cheron RG, Dluhy R, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981; 304 (6): 319-24
11. Malcovati L, Della Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005 Oct 20; 23 (30): 7594-603
12. Greenberg P, Baer M, Bennett J, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006 Jan; 4 (1): 58-77
13. Alessandrino EP, Amadori S, Barosi G, et al. Evidence and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes: a statement from the Italian Society of Hematology. Haematologica 2002; 87: 1286-306
14. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120: 187-200
15. Wolfe L, Olivieri N, Sallan D, et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985 Jun 20; 312 (25): 1600-3
16. Jensen PD, Jensen FT, Christensen T, et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with desferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 2003; 101: 4632-9
17. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on hematopoiesis in MDS patients with transfusional iron overload. Br J Hematol 1996; 94 (2): 288-99
18. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995 Jan; 89 (1): 67-71
19. Hellstrom-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Hematol 1997; 99: 344-51
20. Miller K, Haesook K, Greenberg P, et al. Phase III prospective randomized trial of EPO with or without G-CSF versus supportive therapy alone in the treatment of myelodysplastic syndromes (MDS): results of the ECOG-CLSG Trial (E1996) [abstract]. Blood 2004; 104: 70
21. Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317: 1545-52
22. Antin JH, Smith BR, Holmes W, et al. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72: 705-13
23. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Hematol 2005; 128: 204-9
24. Mannone L, Gardin C, Quarre MC, et al. High response rate to darbepoetin alfa in "low risk MDS": results of a phase II study. Blood 2004; 104: 69a
25. Gabrilove J, Paquette R, Lyons R, et al. Darbepoetin alfa for the treatment of anemia in patients with low risk myelodysplastic syndrome. MASCC/ISOO 17th International Symposium; 2005 Jun 30-Jul 2; Geneva
26. Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19: 4165-72
27. Tsimberidou AM, Giles FJ, Khouri I, et al. Low-dose interleukin-11 in patients with bone marrow failure: update of the MD Anderson Cancer Center experience. Ann Oncol 2005; 16: 139-45
28. Cheson BD, Jasperse DM, Simon R, et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986; 4: 1857-64
29. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 1998; Suppl. 1: S17-21
30. Winter JN, Variakojis D, Gaynor ER, et al. Low dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia. Cancer 1985; 56: 443-9
31. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001; 98: 3575-83
32. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodys plastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326-31
33. Bennett JM, Young MS, Liesveld JL. Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study. Am J Hematol 2001; 66: 23-7
34. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969-77
35. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312-20
36. Ossenkoppele GJ, van der Holt B, Verhoef GE, et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group: Dutch-Belgian Hemato-Oncology Cooperative Group. Leukemia 1999; 13 (8): 1207-13
37. de Witte T, Hermans J, Vossen J, et al. Haematopoeitic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 620-30
38. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 1996; 87: 51-8
39. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188-94
40. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004
41. Guardiola PH, Fibbe W, Ruutu T, et al. Outcome of patients with myelodysplastic syndromes (MDS) undergoing allogeneic myeloablative transplantation: a retrospective analysis comparing HLA matched unrelated donor bone marrow transplantation (BMT) to HLA identical sibling SCT: a retrospective study on behalf of the EBMT - Chronic Leukemia Working Party. Blood (ASH Annual Meeting Abstracts) 2004; 104: 1427
42. de Lima M, Shahjahan M, Alamo J, et al. Allogeneic hematopoietic stem cell transplantation (HSCT) for patients aged 65 years or older with AML and MDS. Blood (ASH Annual Meeting Abstracts) 2004; 104: 2301
43. De Witte T, Van Biezen A, Hermans J, et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 1997; 90: 3853-7
44. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 1996; 88: 358-65
45. Solomon SR, Childs R, Montero A, et al. Improved outcomes for peripheral blood stem cell transplantation in advanced myelodysplastic syndrome. Blood (ASH Annual Meeting Abstracts) 2004; 104: 2304
46. Martino R, Caballero MD, Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced- intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-5
47. Flynn C, Barker JN, Miller JS, et al. Reduced intensity compared to high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Blood (ASH Annual Meeting Abstracts) 2004; 104: 1817
48. Claus R, Lubbert M. Epigenetic targets in hematopoetic malignancies. Oncogene 2003; 22: 6489-96
49. Leone G, Teofili L, Voso MT, et al. DNA methylation and demthylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324-41
50. Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985-90
51. Karon M, Sieger L, Leimbrock S, et al. 5-azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973; 42: 359-65
52. Christman J. 5-azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483-95
53. Zwiebel JA. New agents for acute myelogenous leukemia. Leukemia 2000; 14: 488-90
54. Wang C, McCullock EA. Sensitivity to 5-azacytidine of blast progenitors in acute myeloblastic leukemia. Blood 1987; 69: 553-9
55. El-Osta A. The rise and fall of genomic methylation in cancer. Leukemia 2004; 18: 233-7
56. Von Hoff DD, Slavik M, Muggia FM. 5-azacytidine: a new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 1976; 85: 237-45
57. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodys plastic syndromes. Leukemia 1993; 7 Suppl. 1: 21-9
58. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20: 2429-40
59. Kaminskas E, Farrell A, Abraham S, FDA, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 2005; 11: 3604-8
60. Lubbert M, Wijermans PW, Ruter BH. Re-treatment with low-dose 5-aza-2′-deoxycytidine (decitabine) results in second remissions of previously responsive MDS patients. Blood (ASH Annual Meeting Abstracts) 2004; 104: 1447
61. Issa J-P, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-40
62. Kantarjian HM, Ravandi F, O'Brien S, et al. Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS): comparison of 3 different dose schedules. Blood (ASH Annual Meeting Abstracts) 2004; 104: 1437
63. Saba H, Rosenfeld C, Issa J-P, et al. First report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 2004; 104: 67
64. Gore SD, Weng LJ, Zhai S, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001; 7 (8): 2330-9
65. Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusion of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2002; 8 (4): 963-70
66. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004; 104: 1266-9
67. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndrome. Br J Cancer 1999; 81: 1398-401
68. Hamblin TJ. Immunological abnormalities in myelodysplastic syndrome. Semin Hematol 1996; 33: 150-62
69. Bellamy W, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 1427-34
70. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 958-65
71. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549-57
72. List AF, Gewald G, Bennett J, et al. Hematologic and cytogenetic response to lenalidomide (CC-5013; REVLIMID) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study [abstract no. 5]. ASCO Annual Meeting; 2005 May 13-17; Orlando (FL)
73. List AF, Gewald G, Bennett J, et al. Results of the MDS-002 and -003 international phase II studies evaluating lenalidomide (CC-5013; Revlimid) in the treatment of transfusion-dependent patients with myelodysplastic syndrome (MDS). 10th Congress European Hematology Association (EHA); 2005 Jun 2-5; Stockholm
74. List AF, Schiller GJ, Mason J, et al. Trisenox (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary findings in a phase 2 clinical study [abstract]. Blood 2003; 102: 1539a
75. Raza A, Lisak L, Tahir S, et al. Trilineage response to arsenic trioxide (trisenox) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2) [abstract]. Blood 2002; 100: 3142
76. Gotlib J, Jamieson C, List A, et al. Phase II study of bevacizumab (anti-VEGF humanized monoclonal antibody) in patients with meylodysplastic syndrome (MDS) [abstract]. Blood 2003; 102 Suppl. 1: 425a
77. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001 Mar 1; 97 (5): 1413-21
78. Giles FJ, Stopeck AT, Silverman LR, et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102: 795-801
79. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005; 23: 4162-71
80. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anemias without hypoplastic bone marrow. Br J Hematol 1998; 100: 304-9
81. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Hematol 1997; 99: 699-705
82. Killick S, Mufti G, Cavenagh J, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low risk' myelodysplasia. Br J Hematol 2003; 120: 679-84
83. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156-63
84. Barrett AJ, Molldrem JJ, Saunthrajarian Y, et al. Prolonged transfusion independence and disease stability in patients with myelodysplastic syndrome (MDS) responding to antithymocyte globulin (ATG) [abstract]. Blood 1998; 92: 713a
85. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-7
86. Barrett AJ, Sloan E, Greenberg P, et al. Immunsuppressive treatment for myelodys plastic syndrome. Bone Marrow Failure Scientific Symposium; 2005 Oct 17-19; Washington (DC), 11a
87. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001; 97: 3361-9
88. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-9
89. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 2003; 102: 4527-34
90. Kurzrock R, Albitar M, Cortes JE, et al. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 2004; 22: 1287-92
91. Lancet JE, Gotlib J, Gojo I, et al. Tipifarnib (ZARNESTRATM) in previously untreated poor-risk AML of the elderly: updated results of a multicenter phase 2 trial [abstract]. Blood (ASH Annual Meeting Abstracts) 2004 Nov; 104: 874
92. Feldman EJ, Cortes J, Holyoake T, et al. Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome [abstract]. Blood 2003; 102: 176
93. Cortes J, Holyoake T, Silver R. Continuous oral lonafarnib (Sarasar) for the treatment of patients with advanced hematologic malignancies: a phase II study [abstract]. Blood 2002; 100: 3132
94. Buresh A, Perentesis J, Rimsza L, et al. Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia 2005; 19: 308-10
95. Apperley JF, Gardembas M, Melo JV, et al. Response to Imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481-7
96. Shetty V, Sanoy A, Payne G, et al. High degree of TNF-a may be responsible for extensive apoptosis of bone marrow cells in MDS. Cell Prolif 1994; 27 (2): 411a
97. Stasi R, Amadori S, Newland A, et al. Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma 2005; 46 (4): 509-16
98. Raza A, Candoni A, Khan U, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 2004; 45 (10): 2099-104